Status:
TERMINATED
Rosiglitazone-Induced Weight Gain
Lead Sponsor:
Stanford University
Collaborating Sponsors:
GlaxoSmithKline
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
20-75 years
Phase:
NA
Brief Summary
Given the high prevalence of type 2 diabetes and the 2- to 4-fold increased risk of fatal and non-fatal coronary heart disease events in these patients, long-term glycemic control is of great importan...
Detailed Description
Study Design Randomized, controlled trial. Volunteers for the study will be recruited by advertisements in the local newspapers as well as through Stanford University e-mail. All studies will occur at...
Eligibility Criteria
Inclusion
- 1) age between 30 and 70 years old, 2) normal chemical screening battery, 2) BMI less than 36 kg/M2, 3) non-controlled type 2 DM, defined by a fasting plasma glucose between 160 and 220 mg/dl, 4) individuals should be on a stable dose of sulfonylurea for at least one month prior to the enrollment.
Exclusion
- 1) liver enzymes 2.5 times above normal values, 2) chronic inflammatory, neoplastic disease, 3) subjects with clinical evidence of congestive heart failure.
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2005
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00225225
Start Date
October 1 2002
End Date
September 1 2005
Last Update
October 20 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305